Please login to the form below

Not currently logged in

Roche stops supplies for Greek hospitals

Roche has cancelled the delivery of drugs to some hospitals in Greece over unpaid bills dating back up to four years, said the pharmaceutical company's CEO Severin Schwan

Roche has cancelled the delivery of drugs for the treatment of cancer and other diseases to some hospitals in Greece over unpaid bills dating back up to four years.

The comments were made by the pharmaceutical company's CEO Severin Schwan in an interview with the Wall Street Journal in which he said the same measures may be taken in other European countries, such as Spain, Italy and Portugal.

The move follows a decision by Novo Nordisk last year to cancel supplies of modern insulin products to the country that is undergoing severe budget cuts as it attempts to avoid defaulting on its debts. Novo resumed its supply after the country agreed to raise its prices on the drugs following mandatory price cuts earlier in the year.

Schwann said only state-funded hospitals would be affected by Roche's decision and supplies would be boosted for privately run Greek pharmacies.

This means patients at certain hospitals will have to take their prescriptions to a local pharmacy and, in the case of intravenous or injected cancer drugs, bring them back to the hospital to be administered.

Following the supply cut-off, some hospitals had become better at paying bills, according to Schwan, who suggested hospitals did not want to gain a poor reputation with patients.

19th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Serviceplan Health & Life

We are your creative global lead agency, your Pan-European hub and your worldwide network....

Latest intelligence

Building understanding: A day in the life of a GP
Understanding what GPs deal with daily will help you to formulate an effective HCP engagement strategy that works for them...
Pharma Marketing Summit: From ”why” to ”how” in multichannel communications
For the first time we’re sharing our observations of pharma conferences — kicking off with our delegates’ views of the Annual Pharma Marketing Summit in Berlin last month....
Access to orphan drugs for rare cancers in EU28